Company Overview
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Why Investors Should Care
Revenue has grown at a 14.4% CAGR over the past five years.
Recent Developments
- Apr 2026 Revenue of $59.42M (+4.4% YoY); net profit $-1.18M.
- Trailing 12 Months Year-on-year growth — revenue +12.0%, earnings -125.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.41% |
| 1 Year: | 12.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -124.99% |
Stock Price Performance
| 1 Year: | -26.17% |
| 6 Months: | -15.41% |
| 3 Months: | -10.46% |
| 1 Month: | -2.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.4% over 5 years.
CONS
- Trading 39.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CSBR Champions Oncology, Inc. PHARMA | 5.05 | -63.12 | $70.29M | 0.00% | -16.13% | -29.97% | 14.41% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2013 | Jul 2013 | Oct 2013 | Jan 2014 | Jul 2014 | Oct 2014 | Jan 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.43M | 6.74M | 7.62M | 9.01M | 9.55M | 10.12M | 10.81M | 11.25M | 11.79M | 13.19M | 13.74M | 14.28M | 12.77M | 12.56M | 11.57M | 12.02M | 14.06M | 13.49M | 17.04M | 13.99M | 15.04M | 16.56M |
| Operating Income | -720.00K | -766.00K | -1.70M | -1.41M | -3.73M | -3.67M | -3.42M | -2.90M | -2.49M | -2.37M | -2.52M | -493.00K | -1.40M | -619.00K | -70.00K | -67.00K | 481.00K | 275.00K | -370.00K | -614.00K | 291.00K | 433.00K | 24.00K | 7.00K | 982.00K | -175.00K | 263.00K | 830.00K | -284.00K | 7.00K | -2.46M | -2.55M | -1.96M | -2.58M | 1.33M | 732.00K | 4.50M | -527.00K | 185.00K | -276.00K |
| Net Income | -990.00K | -2.23M | -2.32M | -574.00K | -3.55M | -3.08M | -2.82M | -2.91M | -2.55M | -2.41M | -2.55M | -504.00K | -1.41M | -674.00K | -94.00K | -76.00K | 483.00K | 267.00K | -369.00K | -641.00K | 307.00K | 75.00K | 75.00K | 1.00K | 959.00K | -172.00K | 277.00K | 787.00K | -319.00K | -16.00K | -2.44M | -2.57M | -2.07M | -2.53M | 1.31M | 728.00K | 4.50M | -436.00K | 268.00K | -279.00K |
| Diluted EPS | - | - | -0.03 | -0.02 | -0.64 | -0.65 | -0.61 | -0.33 | -0.29 | -0.28 | - | - | - | -0.06 | -0.01 | -0.01 | 0.04 | 0.02 | -0.03 | -0.06 | 0.02 | 0.03 | 0.01 | 0.00 | 0.07 | -0.01 | 0.02 | 0.05 | -0.02 | 0.00 | -0.18 | -0.19 | -0.15 | -0.19 | 0.09 | 0.05 | 0.31 | -0.03 | 0.02 | -0.02 |
| R&D Expense | 592.00K | 402.00K | 677.00K | 535.00K | 1.42M | 1.25M | 1.09M | 1.10M | 919.00K | 999.00K | 1.21M | 1.01M | 998.00K | 1.12M | 1.11M | 1.04M | 1.09M | 1.19M | 1.27M | 1.30M | 1.34M | 1.39M | 1.60M | 1.65M | 1.88M | 2.30M | 2.30M | 2.18M | 2.89M | 2.60M | 3.20M | 2.79M | 2.52M | 2.19M | 1.45M | 1.69M | 1.72M | 2.08M | 2.62M | 2.27M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 20.24M | 27.07M | 32.12M | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M | 59.42M |
| Operating Income | -5.24M | -9.06M | -6.22M | -6.26M | -13.24M | -10.32M | -6.81M | -1.35M | 270.00K | -1.92M | 366.00K | 607.00K | -5.26M | -7.36M | 4.55M | -1.14M |
| Net Income | -3.80M | -8.66M | -6.33M | -7.41M | -13.14M | -10.45M | -6.88M | -1.48M | 128.00K | -2.09M | 362.00K | 548.00K | -5.33M | -7.28M | 4.70M | -1.18M |
| Diluted EPS | - | - | - | -0.11 | -2.20 | -1.20 | - | -0.13 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.08 |
| R&D Expense | 2.91M | 2.94M | 1.92M | 2.27M | 4.84M | 4.19M | 4.29M | 4.40M | 4.80M | 5.85M | 7.20M | 9.37M | 11.54M | 9.54M | 6.83M | 9.08M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2010 | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Jan 2021 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 12.65M | 6.92M | 11.65M | 8.87M | 12.05M | 5.78M | 8.01M | 8.08M | 11.27M | 20.75M | - | 27.59M | 35.38M | 34.31M | 26.13M | 32.34M | 26.99M |
| Total Equity | 1.58M | 19.00K | -5.28M | -9.21M | 3.20M | 8.06M | 238.00K | 400.00K | 3.00K | 2.14M | 5.10M | 8.09M | 7.43M | 9.10M | 4.64M | -1.90M | 3.77M | 3.94M |
| Cash & Equivalents | 2.57M | 10.46M | 4.75M | 9.56M | 5.89M | 9.36M | 2.58M | 3.29M | 856.00K | 3.24M | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.47M | 4.04M | 3.98M | 5.67M | 3.99M | 5.54M | 7.61M | 8.07M | 9.03M | 15.65M | 17.17M | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M | 22.92M |
| Current Liabilities | - | 3.50M | 3.49M | 2.93M | 3.66M | 3.80M | 5.31M | 7.45M | 7.45M | 8.03M | 12.30M | 11.20M | 11.20M | 17.48M | 21.73M | 21.54M | 23.85M | 19.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -54.00K | -5.23M | -4.29M | - | -9.63M | -6.41M | -2.84M | -1.23M | 1.86M | 2.90M | -1.68M | 6.50M | 3.97M | -6.14M | 7.39M | -4.47M |
| Investing Cash Flow | -84.00K | -519.00K | -57.00K | - | -114.00K | -322.00K | -766.00K | -1.23M | -834.00K | -2.22M | -3.17M | -2.38M | -2.87M | -836.00K | -389.00K | -540.00K |
| Financing Cash Flow | 8.08M | 97.00K | 9.14M | - | 13.21M | -42.00K | 4.32M | 13.00K | 1.20M | 4.42M | 1.20M | 207.00K | 11.00K | -527.00K | 170.00K | 99.00K |
| Capital Expenditure | -85.00K | -519.00K | -57.00K | -234.00K | -119.00K | -322.00K | -766.00K | -1.23M | -834.00K | -2.22M | -3.28M | -2.38M | -2.87M | -836.00K | -389.00K | -564.00K |
| Free Cash Flow | -139.00K | -5.75M | -4.35M | - | -9.75M | -6.73M | -3.61M | -2.46M | 1.03M | 685.00K | -4.96M | 4.11M | 1.10M | -6.97M | 7.00M | -5.04M |
| Share Buybacks | 1.03M | 0 | - | - | - | - | - | - | - | - | - | 0 | 74.00K | 634.00K | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -6.7% | 1.0% | -6.0% | 0.9% | 1.2% | -9.8% | -14.7% | 8.0% | -1.9% |
| Net Margin % | - | - | - | - | - | - | - | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% | -2.0% |
| ROE % | -20,010.5% | 164.1% | 68.8% | -231.7% | -163.0% | -4,388.9% | -1,721.0% | -49,200.0% | 6.0% | -41.0% | 4.9% | 6.0% | -115.1% | 382.3% | 124.6% | -29.8% |
| ROCE % | -57.2% | -263.8% | -71.3% | -120.2% | -160.4% | -2,190.2% | -1,207.3% | -216.6% | 8.3% | -22.7% | 2.2% | 3.4% | -41.8% | -160.2% | 53.6% | -16.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Battery Management Corp. | 17.40% | 2.42M | $12.83M |
| 2 | NEA Management Company, LLC | 12.31% | 1.71M | $9.08M |
| 3 | Vanguard Capital Management LLC | 2.17% | 301.35K | $1.60M |
| 4 | Tocqueville Asset Management L.p. | 2.12% | 295.66K | $1.57M |
| 5 | Morgan Stanley | 1.69% | 235.40K | $1.25M |
| 6 | Bank of America Corporation | 1.54% | 214.06K | $1.13M |
| 7 | Renaissance Technologies, LLC | 1.00% | 139.04K | $736.91K |
| 8 | Blackrock Inc. | 0.93% | 129.85K | $688.19K |
| 9 | Mink Brook Asset Management LLC | 0.80% | 111.34K | $590.09K |
| 10 | Geode Capital Management, LLC | 0.55% | 76.30K | $404.39K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CSBR
Responsive Playbooks and the CSBR Inflection - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNYXFudTJ1WTU2QUpqR3pCc0FTR2cyZlNfdzZGYU5BZmxmM3hDa1ZEN09QVEhGSTUtSWZndHdCeEY2bXlhNlBWbWpDYlZkSnRjcG5FZG5mUTNOZ1lsWnhOTnZqOVpEQktQRUJvY25yeDB1emxDNFlPTzVWQl84QURPWm9YT0RILW9xOHhkeX…
A cancer research company will report results Sept. 10 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOU3dDOEM3VS13SGstZHpVUkMyQmdfYzRDVnktNG5SQ3oxVG5LN0xkZ2t1TVBrZ3FKMHpsZVRSOGJUZy1lNEh0TDJyYV9iWFZsTEJwbnFZUV9kbVZ3ZzVoaFRGWWpfbGF2Y2lZLWJoWnptZm1xQkcwN0FUU3pIUDh1VUNTLUNnRnk1dXB2TF…
Champions Oncology, Inc. (CSBR) Stock Price & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE9HLWk2bS1Qb3paUnBjUDBtQkJTektUdDRQLThRZmFOMTNGOEFDUGtiQ1BSQWplVk1NSjFaVHFweGpDWDlqSzRXY0l2Yw?oc=5" target="_blank">Champions Oncology, Inc. (CSBR) Stock Price & News</a>  …
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNbnFPcDVsWTlOb2QwUWJETXFrUlZfLTZ1cVJsU1JqSFJVYTlYTjVsajNnWnRCUXkwU2F0VzRiQmZmTXFmbE8yRUVMZVREdHRlZWdNV2thNHFpemJGMXNzMDlvaUpubzREalpsRm82SktwWUlvMnhjRjc1emgtdDZUVmtWRmt1Y1VFS0hfOG…
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOemZhalBRMjA5cjFjcGlvUG5EZ1Z0UTFrMlJJQm1wbi1tOFdfMVVKWldOVjZtZ1JydGVvLWRKTjJWbDBTRl80cmwzdl9LcmlsNFcxQ2oxX0Fua050ZlhCRGp1WEpwM1FVS0ZQMUpPMzl1ZjN1OTV2WlJ6UHdBbnFEa3J4REl3S1p4V2N3LV…
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQak9kNU1xZFlVVkdQbGIzUTA5bUMyYWVYdTJTT3h1OGVOTEZDUklTdTRjSGdhZk9vaXVJdGFzeU1UV21DWURVN0ZhNVBMTExHMmRpc2xmM0NvZzBOTklaVU5YNFNwdDlNWm5vRkg0UW9XRFJJai05YnNTcVNQbC15cm1GMnROTHhWRXQzM3…
CSBR — Frequently Asked Questions
What is the current share price of Champions Oncology, Inc. (CSBR)?
As of 2026-09-19 21:16 PDT, Champions Oncology, Inc. (CSBR) trades at $5.05 on NasdaqCM. Its 52-week range is $4.92 to $8.30.
What is the market capitalisation of CSBR?
Champions Oncology, Inc. (CSBR) has a market capitalisation of $70.29M on NasdaqCM.
What is the P/E ratio of CSBR?
CSBR trades at a trailing price-to-earnings (P/E) ratio of -63.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 17.64.
What is the return on equity (ROE) of CSBR?
CSBR has a return on equity (ROE) of -29.97%. Its return on capital employed (ROCE) is -16.13%.
Is CSBR a good stock to buy?
This page provides a data-driven analysis of Champions Oncology, Inc. (CSBR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.